PEDIATRIC LOW GRADE ASTROCYTOMA--TREATMENT GUIDANCE
儿童低度星形细胞瘤——治疗指南
基本信息
- 批准号:2461212
- 负责人:
- 金额:$ 14.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-12-12 至 1999-11-30
- 项目状态:已结题
- 来源:
- 关键词:apoptosis astrocytoma cell proliferation child (0-11) choline clinical research clinical trials electron spin resonance spectroscopy human subject human therapy evaluation immunocytochemistry neoplasm /cancer chemotherapy neoplasm /cancer radiation therapy outcomes research pediatric neoplasm /cancer pediatric pharmacology prognosis tissue /cell culture
项目摘要
DESCRIPTION: Clinical outcome in cases of pediatric low grade astrocytoma
(LGA), the single most common type of solid tumor in children, is
unpredictable. Although complete resection is often curative, this is not
possible, in many instances, because LGA tends to invade midline brain
structures having essential systemic physiological significance. After
partial resection, LGA may remain stable, may continue to grown, or may
undergo malignant transformation. Even modest postoperative growth can
result in severe neurological deficits or death. After partial resection,
several adjunctive management options are available for biologically
aggressive tumors. Fractionated radiation therapy or chemotherapy may be
used, but these options are often deferred as long as possible to avoid
therapy-attributable developmental problems. Stereotactic radiation therapy
may be used to ablate aggressive tumor foci ("pruning") as a means of
controlling volumetric growth thereby permitting the child to develop to the
point where global radiation therapy or chemotherapy can be considered.
Conventional diagnostic neuroimaging methods are unable to identify
biologically aggressive LGA so that adjunctive therapy may be offered nor
are they capable of identifying the location of tumor subvolumes exhibiting
aggressive characteristics for "pruning". We hypothesize that choline
signal measures obtained from newly developed proton magnetic resonance
spectroscopic imaging (1H-MRSI) technology will overcome these shortcomings.
The hypothesis is based on studies which suggest that choline signal levels
are related proliferative activity and on our own work which has shown that
histopathologically homogeneous LGA cases exhibit heterogeneous patterns of
tumoral choline signal. The hypothesis will be tested with
clinical/laboratory correlation study and two pilot clinical trials. In the
clinical/laboratory correlation study, pre-operative determination of
metabolically relevant regions of interest with 1H-MRSI will be followed by
intra-surgical excision of samples identified. These will be analyzed
immunocytochemically for proliferative and apoptosis characteristics. In
the clinical pilot trials, we will seek to establish that post-therapy
choline measures are predictive of future growth and that 1H-MRSI may be
used in target planning for focal therapies.
描述:儿童低级别星形细胞瘤病例的临床结局
(LGA)是儿童中最常见的一种实体瘤,
不可预测 虽然完全切除往往是治愈,这是不是
在许多情况下,这是可能的,因为LGA倾向于侵入中线脑
具有重要的全身生理意义的结构。 后
部分切除后,LGA可能保持稳定,可能继续生长,或者可能
经历恶性转化。 即使是适度的术后生长,
导致严重的神经功能缺损或死亡。 部分切除后,
有几种连续的管理方法可供生物学上使用,
侵袭性肿瘤 分次放疗或化疗可能
使用,但这些选项往往被推迟,只要可能,以避免
治疗引起的发育问题。 立体定向放射治疗
可用于消融侵袭性肿瘤病灶(“修剪”),
控制体积生长,从而允许儿童发育到
可以考虑进行全身放疗或化疗。
传统的诊断神经成像方法无法识别
生物侵袭性LGA,以便可以提供连续治疗,
它们是否能够识别肿瘤亚体积的位置,
“修剪”的侵略性特征。 我们假设胆碱
从新开发的质子磁共振获得的信号测量
光谱成像(1H-MRSI)技术将克服这些缺点。
这一假设是基于研究表明胆碱信号水平
与增殖活性有关,我们自己的研究表明,
组织病理学均质LGA病例表现出异质性模式,
肿瘤胆碱信号。 该假设将被测试,
临床/实验室相关性研究和两项试点临床试验。 在
临床/实验室相关性研究,术前确定
1H-MRSI的代谢相关感兴趣区域将随后进行
确定的样本的术中切除。 这些将被分析
免疫细胞化学检测增殖和凋亡特征。 在
临床试验,我们将寻求建立治疗后
胆碱测量可预测未来的生长,1H-MRSI可能是
用于局部治疗的目标规划。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffry R Alger其他文献
Jeffry R Alger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffry R Alger', 18)}}的其他基金
Mapping brain glutamate in humans: sex differences in cigarette smokers
绘制人类大脑谷氨酸图谱:吸烟者的性别差异
- 批准号:
10376214 - 财政年份:2021
- 资助金额:
$ 14.15万 - 项目类别:
Novel Algorithms for Reducing Radiation Dose of CT Perfusion
减少 CT 灌注辐射剂量的新算法
- 批准号:
10220967 - 财政年份:2017
- 资助金额:
$ 14.15万 - 项目类别:
Novel Algorithms for Reducing Radiation Dose of CT Perfusion
减少 CT 灌注辐射剂量的新算法
- 批准号:
10006737 - 财政年份:2017
- 资助金额:
$ 14.15万 - 项目类别:
VALIDATION OF MAGNETIC RESONANCE PERFUSION IMAGING
磁共振灌注成像的验证
- 批准号:
6193264 - 财政年份:2000
- 资助金额:
$ 14.15万 - 项目类别:
VALIDATION OF MAGNETIC RESONANCE PERFUSION IMAGING
磁共振灌注成像的验证
- 批准号:
6394294 - 财政年份:2000
- 资助金额:
$ 14.15万 - 项目类别:
VALIDATION OF MAGNETIC RESONANCE PERFUSION IMAGING
磁共振灌注成像的验证
- 批准号:
6603227 - 财政年份:2000
- 资助金额:
$ 14.15万 - 项目类别:
VALIDATION OF MAGNETIC RESONANCE PERFUSION IMAGING
磁共振灌注成像的验证
- 批准号:
6540203 - 财政年份:2000
- 资助金额:
$ 14.15万 - 项目类别:
RESEARCH ANIMAL MAGNETIC RESONANCE IMAGING INSTRUMENT
研究动物磁共振成像仪
- 批准号:
2864968 - 财政年份:1999
- 资助金额:
$ 14.15万 - 项目类别:
PEDIATRIC LOW GRADE ASTROCYTOMA--TREATMENT GUIDANCE
儿童低度星形细胞瘤——治疗指南
- 批准号:
2837789 - 财政年份:1997
- 资助金额:
$ 14.15万 - 项目类别:
相似海外基金
A Phase 2 biomarker driven, Study of DB107, a Retroviral Replicating Vector, Combined With 5-FC in Patients with Recurrent Glioblastoma or Anaplastic Astrocytoma
由生物标志物驱动的 DB107(一种逆转录病毒复制载体)与 5-FC 联合治疗复发性胶质母细胞瘤或间变性星形细胞瘤患者的 2 期研究
- 批准号:
10722246 - 财政年份:2023
- 资助金额:
$ 14.15万 - 项目类别:
Multimodality Neuroimaging Evaluation of Cognitive Functioning in Lower Grade Astrocytoma
低级别星形细胞瘤认知功能的多模态神经影像评估
- 批准号:
10701775 - 财政年份:2022
- 资助金额:
$ 14.15万 - 项目类别:
Targeting metabolic vulnerabilities in Astrocytoma, IDH-mutant, Grade 4
针对星形细胞瘤、IDH 突变、4 级的代谢脆弱性
- 批准号:
10306229 - 财政年份:2021
- 资助金额:
$ 14.15万 - 项目类别:
Targeting metabolic vulnerabilities in Astrocytoma, IDH-mutant, Grade 4
针对星形细胞瘤、IDH 突变、4 级的代谢脆弱性
- 批准号:
10491830 - 财政年份:2021
- 资助金额:
$ 14.15万 - 项目类别:
metabolome analysis focusing on the malignant transformation of astrocytoma
关注星形细胞瘤恶性转化的代谢组分析
- 批准号:
19K09520 - 财政年份:2019
- 资助金额:
$ 14.15万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Exploring the tumorigenesis of H3F3A mutations in pediatric high-grade astrocytoma (HGA) and Giant cell tumor of the bone (GCTB).
探索儿童高级星形细胞瘤 (HGA) 和骨巨细胞瘤 (GCTB) 中 H3F3A 突变的肿瘤发生。
- 批准号:
377032 - 财政年份:2017
- 资助金额:
$ 14.15万 - 项目类别:
Fellowship Programs
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
M032(一种表达 IL-12 的基因工程 HSV-1)在复发/进行性多形性胶质母细胞瘤、间变性星形细胞瘤或胶质肉瘤患者中的 1 期研究。
- 批准号:
9455636 - 财政年份:2017
- 资助金额:
$ 14.15万 - 项目类别:
Defining the role of the histone 3 (H3.3G34R) mutation in the pathogenesis of pediatric high grade astrocytoma
定义组蛋白 3 (H3.3G34R) 突变在儿童高级星形细胞瘤发病机制中的作用
- 批准号:
368929 - 财政年份:2017
- 资助金额:
$ 14.15万 - 项目类别:
Operating Grants
Detection and clinical application of pilocytic astrocytoma minimal residual disease
毛细胞型星形细胞瘤微小残留病的检测及临床应用
- 批准号:
16K10011 - 财政年份:2016
- 资助金额:
$ 14.15万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Origin of the microvascular proliferation in pilocytic astrocytoma
毛细胞型星形细胞瘤微血管增殖的起源
- 批准号:
16K10763 - 财政年份:2016
- 资助金额:
$ 14.15万 - 项目类别:
Grant-in-Aid for Scientific Research (C)